We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

186 hedge funds and large institutions have $541M invested in Meridian Bioscience Inc in 2018 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 68 increasing their positions, 57 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more call options, than puts

Call options by funds: $1.05M | Put options by funds: $581K

59% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 17

19% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 57

4% more funds holding

Funds holding: 178186 (+8)

0% more capital invested

Capital invested by funds: $539M → $541M (+$1.72M)

Holders
186
Holders Change
+8
Holders Change %
+4.49%
% of All Funds
4.26%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
27
Increased
68
Reduced
57
Closed
17
Calls
$1.05M
Puts
$581K
Net Calls
+$471K
Net Calls Change
-$504K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$76.4M +$1.62M +109,220 +2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$59.5M -$163K -10,983 -0.3%
BCM
3
Brown Capital Management
Maryland
$56.9M -$9.72M -656,904 -14%
Renaissance Technologies
4
Renaissance Technologies
New York
$34.2M +$2.67M +180,100 +8%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$25.8M +$457K +30,913 +2%
State Street
6
State Street
Massachusetts
$16.6M -$1.3M -87,693 -7%
Norges Bank
7
Norges Bank
Norway
$16.1M -$71.9K -4,856 -0.4%
PP
8
Prudential plc
United Kingdom
$14.8M +$1.76M +119,200 +13%
SFM
9
Systematic Financial Management
New Jersey
$14.4M +$1.91M +128,953 +15%
Millennium Management
10
Millennium Management
New York
$11.9M -$4.35M -294,156 -26%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$11.3M +$60K +4,055 +0.5%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$10.5M +$614K +41,512 +6%
JP Morgan Chase
13
JP Morgan Chase
New York
$8.43M -$435K -29,425 -5%
Charles Schwab
14
Charles Schwab
California
$8.06M +$1.43M +96,305 +20%
New York State Common Retirement Fund
15
New York State Common Retirement Fund
New York
$8.03M -$7.31M -493,653 -47%
Northern Trust
16
Northern Trust
Illinois
$7.81M +$57.9K +3,914 +0.7%
Deutsche Bank
17
Deutsche Bank
Germany
$7.28M +$1.35M +91,237 +22%
AL
18
AJO LP
Pennsylvania
$6.16M +$6.27M +423,469 +4,042%
Prudential Financial
19
Prudential Financial
New Jersey
$5.53M +$192K +12,952 +3%
Wells Fargo
20
Wells Fargo
California
$5.15M -$2.43M -164,514 -31%
Principal Financial Group
21
Principal Financial Group
Iowa
$4.83M +$146K +9,861 +3%
Morgan Stanley
22
Morgan Stanley
New York
$4.6M -$1.39M -93,750 -22%
Rafferty Asset Management
23
Rafferty Asset Management
New York
$4.43M +$4.62M +311,884 New
PPA
24
Parametric Portfolio Associates
Washington
$4.32M +$1.28M +86,446 +40%
MAM
25
Martingale Asset Management
Massachusetts
$3.81M +$1.29M +87,010 +48%

VIVO Hedge Fund Activity: Q1 2018 in Review

186 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q1 2018, worth a combined $541M — up 0.32% from $539M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new VIVO positions and 17 closed out — a net gain of 10 holders — while 68 added to existing stakes and 57 trimmed.

The largest buyer was AJO LP, adding an estimated $6.27M. The largest seller was Brown Capital Management, cutting an estimated $9.72M.

  • 186 institutional investors held Meridian Bioscience Inc (VIVO) as of Q1 2018, up from 178 in Q4 2017.
  • Funds reported $541M of Meridian Bioscience Inc stock for Q1 2018, up 0.32% quarter-over-quarter.
  • 27 funds opened new Meridian Bioscience Inc positions in Q1 2018 and 17 closed out, a net change of +10 holders.
  • The largest Meridian Bioscience Inc buyer in Q1 2018 was AJO LP, an estimated $6.27M added.
  • The largest Meridian Bioscience Inc seller in Q1 2018 was Brown Capital Management, an estimated $9.72M sold.

Based on aggregated 13F filings for Q1 2018.